FY2026 Earnings Forecast for HRTX Issued By Northland Capmk

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Northland Capmk issued their FY2026 earnings per share (EPS) estimates for Heron Therapeutics in a research report issued on Tuesday, November 4th. Northland Capmk analyst C. Byrnes forecasts that the biotechnology company will earn ($0.05) per share for the year. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

Several other brokerages have also weighed in on HRTX. Wall Street Zen lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Needham & Company LLC decreased their target price on Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.10 on Friday. The firm has a market capitalization of $201.65 million, a PE ratio of -55.00 and a beta of 1.30. Heron Therapeutics has a one year low of $1.04 and a one year high of $2.68. The stock’s 50 day moving average price is $1.25 and its 200 day moving average price is $1.69.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $38.21 million during the quarter, compared to the consensus estimate of $39.03 million. Heron Therapeutics has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Heron Therapeutics by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 8,225,585 shares of the biotechnology company’s stock worth $18,096,000 after buying an additional 67,976 shares during the last quarter. Tejara Capital Ltd boosted its holdings in shares of Heron Therapeutics by 1.6% during the third quarter. Tejara Capital Ltd now owns 4,589,715 shares of the biotechnology company’s stock valued at $5,783,000 after acquiring an additional 72,300 shares during the period. Geode Capital Management LLC grew its position in shares of Heron Therapeutics by 14.6% during the second quarter. Geode Capital Management LLC now owns 3,566,813 shares of the biotechnology company’s stock worth $7,385,000 after acquiring an additional 453,085 shares during the last quarter. JW Asset Management LLC grew its position in shares of Heron Therapeutics by 40.8% during the third quarter. JW Asset Management LLC now owns 3,292,633 shares of the biotechnology company’s stock worth $4,149,000 after acquiring an additional 954,890 shares during the last quarter. Finally, AIGH Capital Management LLC increased its holdings in shares of Heron Therapeutics by 8.3% in the 2nd quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company’s stock worth $6,229,000 after acquiring an additional 231,057 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.